Shanghai - Delayed Quote CNY

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS)

42.91 +0.37 (+0.87%)

At close: 3:00:01 PM GMT+8

Chart Range Bar

Loading chart for 600329.SS

Previous Close 42.54
Open 42.14
Bid 42.90 x --
Ask 42.91 x --
Day's Range 41.95 - 43.30
52 Week Range 33.83 - 50.95
Volume 5,728,373
Avg. Volume 3,335,362
Market Cap (intraday) 33.045B
Beta (5Y Monthly) 0.46
PE Ratio (TTM) 36.99
EPS (TTM) 1.16
Earnings Date --
Forward Dividend & Yield 4.79 (11.89%)
Ex-Dividend Date Jul 10, 2026
1y Target Est --

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. The company was founded in 1915 and is based in Tianjin, the People's Republic of China.

www.jydrt.com.cn

3,890

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Drug Manufacturers - Specialty & Generic

Industry

Trailing total returns as of 11/3/2026, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600329.SS

5.38%

SSE Composite Index (000001.SS)

9.09%

1-Year Return

600329.SS

5.22%

SSE Composite Index (000001.SS)

9.26%

3-Year Return

600329.SS

76.53%

SSE Composite Index (000001.SS)

19.05%

5-Year Return

600329.SS

125.66%

SSE Composite Index (000001.SS)

3.13%

Earnings Per Share

No Earnings Per Share available for this ticker

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q1 FY15

Revenue 1.62B

Earnings --

Profit Margin 0.00%

FY14

FY15

500M

0.0%

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

17.96%
Return on Assets (ttm)

5.13%
Return on Equity (ttm)

11.28%
Revenue (ttm)

4.72B
Net Income Avi to Common (ttm)

848.15M
Diluted EPS (ttm)

1.16

Balance Sheet and Cash Flow

Total Cash (mrq)

3.53B
Total Debt/Equity (mrq)

1.66%
Levered Free Cash Flow (ttm)

1.47B

600332.SS Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

20.25 +1.55%

600380.SS Joincare Pharmaceutical Group Industry Co.,Ltd.

10.30 0.00%

600267.SS Zhejiang Hisun Pharmaceutical Co., Ltd.

12.77 -1.01%

600285.SS Henan Lingrui Pharmaceutical Co., Ltd.

23.59 +4.57%

600351.SS Yabao Pharmaceutical Group Co., Ltd

6.99 -1.83%

U.S. markets closed

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS)

5.02%

21.49%

5.69%

-5.94%

-6.08%

78.27%

285.84%

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Overview Drug Manufacturers - Specialty & Generic / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Recommendations

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch